Melvin Toh

1.3k total citations
20 papers, 1.1k citations indexed

About

Melvin Toh is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Melvin Toh has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Melvin Toh's work include Chronic Myeloid Leukemia Treatments (5 papers), Advances in Cucurbitaceae Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Melvin Toh is often cited by papers focused on Chronic Myeloid Leukemia Treatments (5 papers), Advances in Cucurbitaceae Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Melvin Toh collaborates with scholars based in United States, Belgium and Singapore. Melvin Toh's co-authors include Kin Chan, Wei Xie, Jonathan Said, Nils H. Thoennissen, Ngan Doan, H. Phillip Koeffler, May Garrett, Gabriela B. Iwanski, Carlo L. Bello and Qian Li and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

Melvin Toh

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melvin Toh United States 14 513 295 237 221 168 20 1.1k
Julian C. Desmond United States 18 1.0k 2.0× 117 0.4× 260 1.1× 87 0.4× 50 0.3× 25 1.7k
Siamak Salami Iran 19 557 1.1× 86 0.3× 188 0.8× 86 0.4× 75 0.4× 63 1.1k
Mohamed M. Khalifa Egypt 23 612 1.2× 151 0.5× 150 0.6× 84 0.4× 159 0.9× 49 1.2k
Hsin-Hsiung Tai United States 18 530 1.0× 295 1.0× 238 1.0× 108 0.5× 45 0.3× 25 1.4k
Hong‐Tai Chang Taiwan 21 638 1.2× 103 0.3× 265 1.1× 126 0.6× 43 0.3× 78 1.2k
Bandana Chakravarti India 22 647 1.3× 90 0.3× 155 0.7× 51 0.2× 68 0.4× 41 1.3k
Vasundara Venkateswaran Canada 22 535 1.0× 139 0.5× 176 0.7× 510 2.3× 30 0.2× 47 1.4k
Wen Jing Chung United States 5 631 1.2× 284 1.0× 187 0.8× 55 0.2× 38 0.2× 7 1.4k
Marilyn M. Hinkhouse United States 15 558 1.1× 118 0.4× 116 0.5× 89 0.4× 137 0.8× 26 1.0k
Dingbo Shi China 26 990 1.9× 72 0.2× 347 1.5× 144 0.7× 34 0.2× 46 1.7k

Countries citing papers authored by Melvin Toh

Since Specialization
Citations

This map shows the geographic impact of Melvin Toh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Toh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Toh more than expected).

Fields of papers citing papers by Melvin Toh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Toh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Toh. The network helps show where Melvin Toh may publish in the future.

Co-authorship network of co-authors of Melvin Toh

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Toh. A scholar is included among the top collaborators of Melvin Toh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Toh. Melvin Toh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Zirong, et al.. (2025). 1172 Human TROP2 protein and circRNA vaccines inhibit tumor growth in TROP2-humanized mouse models. Regular and Young Investigator Award Abstracts. A1337–A1337.
2.
Su, Tung‐Ping, et al.. (2016). Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans. Journal of Clinical Sleep Medicine. 12(11). 1453–1459. 5 indexed citations
3.
Wang, Yanfeng, Shuai Qian, Qizhi Zhang, et al.. (2016). Zolpidem Mucoadhesive Formulations for Intranasal Delivery: Characterization, In Vitro Permeability, Pharmacokinetics, and Nasal Ciliotoxicity in Rats. Journal of Pharmaceutical Sciences. 105(9). 2840–2847. 16 indexed citations
4.
Ruiz-Garcı́a, Ana, Brett E. Houk, Yazdi K. Pithavala, et al.. (2015). Effect of axitinib on the QT interval in healthy volunteers. Cancer Chemotherapy and Pharmacology. 75(3). 619–628. 9 indexed citations
5.
Pithavala, Yazdi K., Ying Chen, Melvin Toh, et al.. (2012). Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemotherapy and Pharmacology. 70(1). 103–112. 36 indexed citations
6.
Aribi, Ahmed, Sigal Gery, Der‐Horng Lee, et al.. (2012). The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. International Journal of Cancer. 132(12). 2730–2737. 49 indexed citations
7.
8.
Tortorici, Michael A., Melvin Toh, Sadayappan V. Rahavendran, et al.. (2010). Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Investigational New Drugs. 29(6). 1370–1380. 47 indexed citations
9.
Iwanski, Gabriela B., Ngan Doan, Brandon Castor, et al.. (2010). Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. British Journal of Pharmacology. 160(4). 998–1007. 62 indexed citations
10.
Bello, Carlo L., May Garrett, Laurie Sherman, et al.. (2010). Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemotherapy and Pharmacology. 66(4). 699–707. 31 indexed citations
11.
Thoennissen, Nils H., Gabriela B. Iwanski, Ngan Doan, et al.. (2009). Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells. Cancer Research. 69(14). 5876–5884. 203 indexed citations
12.
Chan, Kin, et al.. (2009). Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Letters. 289(1). 46–52. 112 indexed citations
13.
Khosravan, Reza, Melvin Toh, May Garrett, et al.. (2009). Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function. The Journal of Clinical Pharmacology. 50(4). 472–481. 60 indexed citations
14.
Pithavala, Yazdi K., et al.. (2009). Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemotherapy and Pharmacology. 65(3). 563–570. 66 indexed citations
15.
Bello, Carlo L., Marilyn Mulay, Xin Huang, et al.. (2009). Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib. Clinical Cancer Research. 15(22). 7045–7052. 74 indexed citations
16.
Pithavala, Yazdi K., Melvin Toh, May Garrett, et al.. (2008). Effect of food on the pharmacokinetics of Axitinib (AG-013736) in healthy volunteers. Cancer Research. 68. 233–233. 3 indexed citations
17.
Khosravan, Reza, et al.. (2008). Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis. Journal of Clinical Oncology. 26(15_suppl). 2578–2578. 7 indexed citations
18.
Courtney, Rachel, et al.. (2007). Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor. The Journal of Clinical Endocrinology & Metabolism. 93(2). 550–556. 68 indexed citations
19.
Collie, Alex, Amanda Darekar, Georges Weissgerber, et al.. (2006). Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study. Contemporary Clinical Trials. 28(4). 391–400. 68 indexed citations
20.
Zhou, Jihao, Jie Ling, Michael Amantea, et al.. (2006). OII-A-4Dose-proportionality assessment based on robust statistical methods. Clinical Pharmacology & Therapeutics. 79(2). P4–P4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julian C. Desmond Breakdown of academic impact, for papers by Siamak Salami Breakdown of academic impact, for papers by Mohamed M. Khalifa Breakdown of academic impact, for papers by Hsin-Hsiung Tai Breakdown of academic impact, for papers by Hong‐Tai Chang Breakdown of academic impact, for papers by Bandana Chakravarti Breakdown of academic impact, for papers by Vasundara Venkateswaran Breakdown of academic impact, for papers by Wen Jing Chung Breakdown of academic impact, for papers by Marilyn M. Hinkhouse Breakdown of academic impact, for papers by Dingbo Shi
Rankless by CCL
2026